Daily Policy Digest

Health Issues

The Medical Care Cost Ratchet

A population that is fully insured spends 40 percent to 50 percent more than a population with a large deductible, while gaining no measurable improvement in health status from the additional services...

High Coinsurance Rates Mean High Drug Costs for Patients

Studies of various health plans with a percentage copayment model indicate that consumers may be responsible for up to 50 percent of the cost of specialty drugs, which can cost $8,000 or more each month...

Concierge Medicine Is Not Just for the Wealthy

To bring down the cost of insurance, basic health care maintenance should be divorced from more serious care...

Expanding Medicaid Will Harm Enrollees

Bringing more individuals into Medicaid will only put further strains on a program already struggling to care for those currently enrolled...

The Impact of ObamaCare's "Annual Fee" Tax

Individuals will see their health insurance premiums increase due to ObamaCare's "annual fee" tax by $60 to $160 per person in 2014...

Quality of Non-Domestic Generic Drugs

Sanctions against companies that produce poor-quality products, as well as for U.S. importers of those products, would ensure that drug producers in countries with poor domestic oversight produce good-quality drugs consistently...

Medicare Drug Plans: Don't Mess with Success

If preferred pharmacy networks are banned in 2015, nearly 14 million seniors will lose their Medicare Part D drug plans, says Devon Herrick, a senior fellow at the National Center for Policy Analysis...

Practicing Medicine across State Lines

Doctors must be licensed for each state in which they practice medicine, which makes it difficult for them to care for patients in other states and also poses a hurdle to telemedicine...

Lowest Income Families Will Owe Thousands in ObamaCare Taxes

Measured as a share of after-income, the ObamaCare tax burden on the lowest 20 percent of earners is two times that of the top 20 percent of earners...

Drug Approval Reciprocity between the United States and Europe

Drug approval reciprocity could be limited only to highly developed trading partners as well as to well-understood classes of drugs that have a seriously unmet need, such as cystic fibrosis or cancers...


« Last 8 « Newer « 19 20 21 22 23 24 25 26  Older »